Vitamin E analog α-TEA and celecoxib alone and together reduce human MDA-MB-435-FL-GFP breast cancer burden and metastasis in nude mice

Shuo Zhang, Karla A. Lawson, Marla Simmons-Menchaca, Luzhe Sun, Bob G. Sanders, Kimberly Kline

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

α-TEA, a nonhydrolyzable ether analog of vitamin E (RRR-α-tocopherol), and celecoxib, a specific COX-2 inhibitor, were delivered separately or in combination to investigate their anticancer properties, using MDA-MB-435-FL-GFP human breast cancer xenografts in nude mice. Liposomal formulated α-TEA administered as an aerosol and celecoxib fed at 500 or 1250 mg/kg diet for 31 days separately or in combination significantly reduced tumor volume in comparison to control (p < 0.001 for all treatment groups). Of special note, the combinations of α-TEA + celecoxib (1250) inhibited tumor volume significantly better than either single treatment (p < 0.001 and p < 0.001). Average number of macroscopic lung metastases were significantly reduced in all treatment groups in comparison to control, with the exception of celecoxib (500). Mean numbers of microscopic lung and lymph node metastases in all treatment groups were significantly lower than control. Furthermore, the mean number of microscopic lung metastases in the α-TEA+celecoxib (1250) group were significantly lower than either separate treatment. Analyses of 5 μm tumor sections showed that all treatments, with the exception of celecoxib (500) alone, significantly enhanced apoptosis (TUNEL) and significantly decreased cell proliferation (Ki-67). α-TEA and α-TEA + celecoxib (1250) treatments significantly reduced blood vessel density (CD-31) in comparison to control. These data show promise for combination α-TEA + celecoxib chemotherapy for breast cancer.

Original languageEnglish (US)
Pages (from-to)111-121
Number of pages11
JournalBreast Cancer Research and Treatment
Volume87
Issue number2
DOIs
StatePublished - Sep 2004

Fingerprint

Celecoxib
Vitamin E
Nude Mice
Breast Neoplasms
Neoplasm Metastasis
Tumor Burden
Lung
Therapeutics
Tocopherols
Cyclooxygenase 2 Inhibitors
In Situ Nick-End Labeling
Aerosols
Heterografts
Ether

Keywords

  • apoptosis
  • CD-31
  • celecoxib
  • human MDA-MB-435-FL-GFP breast cancer xenografts
  • Ki-67 nuclear antigen
  • metastasis
  • TUNEL
  • vitamin E analog α-TEA

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Vitamin E analog α-TEA and celecoxib alone and together reduce human MDA-MB-435-FL-GFP breast cancer burden and metastasis in nude mice. / Zhang, Shuo; Lawson, Karla A.; Simmons-Menchaca, Marla; Sun, Luzhe; Sanders, Bob G.; Kline, Kimberly.

In: Breast Cancer Research and Treatment, Vol. 87, No. 2, 09.2004, p. 111-121.

Research output: Contribution to journalArticle

Zhang, Shuo ; Lawson, Karla A. ; Simmons-Menchaca, Marla ; Sun, Luzhe ; Sanders, Bob G. ; Kline, Kimberly. / Vitamin E analog α-TEA and celecoxib alone and together reduce human MDA-MB-435-FL-GFP breast cancer burden and metastasis in nude mice. In: Breast Cancer Research and Treatment. 2004 ; Vol. 87, No. 2. pp. 111-121.
@article{852869e968ef4b0facbcd925e94b029a,
title = "Vitamin E analog α-TEA and celecoxib alone and together reduce human MDA-MB-435-FL-GFP breast cancer burden and metastasis in nude mice",
abstract = "α-TEA, a nonhydrolyzable ether analog of vitamin E (RRR-α-tocopherol), and celecoxib, a specific COX-2 inhibitor, were delivered separately or in combination to investigate their anticancer properties, using MDA-MB-435-FL-GFP human breast cancer xenografts in nude mice. Liposomal formulated α-TEA administered as an aerosol and celecoxib fed at 500 or 1250 mg/kg diet for 31 days separately or in combination significantly reduced tumor volume in comparison to control (p < 0.001 for all treatment groups). Of special note, the combinations of α-TEA + celecoxib (1250) inhibited tumor volume significantly better than either single treatment (p < 0.001 and p < 0.001). Average number of macroscopic lung metastases were significantly reduced in all treatment groups in comparison to control, with the exception of celecoxib (500). Mean numbers of microscopic lung and lymph node metastases in all treatment groups were significantly lower than control. Furthermore, the mean number of microscopic lung metastases in the α-TEA+celecoxib (1250) group were significantly lower than either separate treatment. Analyses of 5 μm tumor sections showed that all treatments, with the exception of celecoxib (500) alone, significantly enhanced apoptosis (TUNEL) and significantly decreased cell proliferation (Ki-67). α-TEA and α-TEA + celecoxib (1250) treatments significantly reduced blood vessel density (CD-31) in comparison to control. These data show promise for combination α-TEA + celecoxib chemotherapy for breast cancer.",
keywords = "apoptosis, CD-31, celecoxib, human MDA-MB-435-FL-GFP breast cancer xenografts, Ki-67 nuclear antigen, metastasis, TUNEL, vitamin E analog α-TEA",
author = "Shuo Zhang and Lawson, {Karla A.} and Marla Simmons-Menchaca and Luzhe Sun and Sanders, {Bob G.} and Kimberly Kline",
year = "2004",
month = "9",
doi = "10.1023/B:BREA.0000041593.69178.57",
language = "English (US)",
volume = "87",
pages = "111--121",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Vitamin E analog α-TEA and celecoxib alone and together reduce human MDA-MB-435-FL-GFP breast cancer burden and metastasis in nude mice

AU - Zhang, Shuo

AU - Lawson, Karla A.

AU - Simmons-Menchaca, Marla

AU - Sun, Luzhe

AU - Sanders, Bob G.

AU - Kline, Kimberly

PY - 2004/9

Y1 - 2004/9

N2 - α-TEA, a nonhydrolyzable ether analog of vitamin E (RRR-α-tocopherol), and celecoxib, a specific COX-2 inhibitor, were delivered separately or in combination to investigate their anticancer properties, using MDA-MB-435-FL-GFP human breast cancer xenografts in nude mice. Liposomal formulated α-TEA administered as an aerosol and celecoxib fed at 500 or 1250 mg/kg diet for 31 days separately or in combination significantly reduced tumor volume in comparison to control (p < 0.001 for all treatment groups). Of special note, the combinations of α-TEA + celecoxib (1250) inhibited tumor volume significantly better than either single treatment (p < 0.001 and p < 0.001). Average number of macroscopic lung metastases were significantly reduced in all treatment groups in comparison to control, with the exception of celecoxib (500). Mean numbers of microscopic lung and lymph node metastases in all treatment groups were significantly lower than control. Furthermore, the mean number of microscopic lung metastases in the α-TEA+celecoxib (1250) group were significantly lower than either separate treatment. Analyses of 5 μm tumor sections showed that all treatments, with the exception of celecoxib (500) alone, significantly enhanced apoptosis (TUNEL) and significantly decreased cell proliferation (Ki-67). α-TEA and α-TEA + celecoxib (1250) treatments significantly reduced blood vessel density (CD-31) in comparison to control. These data show promise for combination α-TEA + celecoxib chemotherapy for breast cancer.

AB - α-TEA, a nonhydrolyzable ether analog of vitamin E (RRR-α-tocopherol), and celecoxib, a specific COX-2 inhibitor, were delivered separately or in combination to investigate their anticancer properties, using MDA-MB-435-FL-GFP human breast cancer xenografts in nude mice. Liposomal formulated α-TEA administered as an aerosol and celecoxib fed at 500 or 1250 mg/kg diet for 31 days separately or in combination significantly reduced tumor volume in comparison to control (p < 0.001 for all treatment groups). Of special note, the combinations of α-TEA + celecoxib (1250) inhibited tumor volume significantly better than either single treatment (p < 0.001 and p < 0.001). Average number of macroscopic lung metastases were significantly reduced in all treatment groups in comparison to control, with the exception of celecoxib (500). Mean numbers of microscopic lung and lymph node metastases in all treatment groups were significantly lower than control. Furthermore, the mean number of microscopic lung metastases in the α-TEA+celecoxib (1250) group were significantly lower than either separate treatment. Analyses of 5 μm tumor sections showed that all treatments, with the exception of celecoxib (500) alone, significantly enhanced apoptosis (TUNEL) and significantly decreased cell proliferation (Ki-67). α-TEA and α-TEA + celecoxib (1250) treatments significantly reduced blood vessel density (CD-31) in comparison to control. These data show promise for combination α-TEA + celecoxib chemotherapy for breast cancer.

KW - apoptosis

KW - CD-31

KW - celecoxib

KW - human MDA-MB-435-FL-GFP breast cancer xenografts

KW - Ki-67 nuclear antigen

KW - metastasis

KW - TUNEL

KW - vitamin E analog α-TEA

UR - http://www.scopus.com/inward/record.url?scp=4544315663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544315663&partnerID=8YFLogxK

U2 - 10.1023/B:BREA.0000041593.69178.57

DO - 10.1023/B:BREA.0000041593.69178.57

M3 - Article

C2 - 15377836

AN - SCOPUS:4544315663

VL - 87

SP - 111

EP - 121

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -